Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
The MDA-supported ALS Therapy Development Institute plans to launch a phase 2 clinical trial of TDI 132, a compound that modulates the immune system
Posted on Tuesday, February 14, 2012 - 11:30, By: Amy Madsen
A phase 2 clinical trial is set to begin of TDI 132, a compound that modulates the immune system, the ALS Therapy Development Institute (ALS TDI) announced today.
TDI 132, also known as fingolimod (brand name Gilenya), already is approved by the U.S. Food and Drug Administration (FDA) for the...